Wells Fargo Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $200

Benzinga · 1d ago
Wells Fargo analyst Mohit Bansal maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $175 to $200.